Eli Lilly plans to submit the NDA in Q4 2026, followed by a 610 month FDA review
Lancet Lond Engl 394:121130 Frias JP, Nauck MA, Van J, Benson C, Bray R, Cui X, Milicevic Z, Urva S, Haupt A, Robins DA (2020) Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens
For some reason I didn't get this for the first two weeks, but have had it consistently since
You may not edit, resell, or re-distribute
Make sure to wait until any postpartum complications are resolved and ensure youre eating enough for recovery
Hypoglycemia is not expected but has been reported, most often in patients who are also using agents known to cause hypoglycemia, such as insulin or sulfonylureas